

May 9, 2023

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

Announcement of Presentation of PPMX-T003 Phase I Progress Report at 118th JSH Kinki Association Meeting

Perseus Proteomics Inc. is pleased to announce that the progress report of phase I clinical trial of PPMX-T003, its anti-transferrin receptor antibody, among polycythemia vera ("PV") patients will be presented at the 118th Japanese Society of Hematology Kinki Association Meeting on May 27, 2023. Its abstract is now available online.

Title: Progress Report of Phase I Clinical Trial Among PV Patients Using
Anti-Transferrin Receptor Antibody (PPMX-T003)

Abstract No: 53

Presenter: Motoki Ito/Professor, Kansai Medical University
(Principal investigator)

The abstract is on the website below (Japanese only):

http://www.jshem.or.jp/uploads/files/local%20branch/%E7%AC%AC118%E5%9B%9E%E8%BF%91%E7%95%BF%E8%A1%80%E6%B6%B2%E5%AD%A6%E4%BC%9A%E3%83%97%E3%83%AD%E3%82%B0%E3%83%A9%E3%83%A0_0502.pdf

In this clinical trial, PPMX-T003 is administered to 6 PV patients to assess its safety and efficacy. As a result of administration to 3 patients, dose-depending efficacy of limiting erythroblast was confirmed. Side effects including transient fever and decrease in lymphocytes were within the range of the results of phase I among healthy volunteers.

At the presentation, data not described in the abstract above will be included. There is no impact on the business results in this fiscal year, however, Mr. Yokokawa considers this presentation will provide favorable effects on the progress of the phase I and obtaining a licensing partner of PPMX-T003, the top priority issue of the Company.

[Contact]

Perseus Proteomics Inc.

Administrative Division e-mail: ir@ppmx.com